SATO VICKI L 4

What Happened

• Vicki L. Sato, a director of Vir Biotechnology (VIR), exercised 42,377 derivative awards (options) on Feb 24, 2026 at an effective exercise price of $1.49 per share (total cost ≈ $62,930). The same day she sold the 42,377 shares in open-market transactions, generating gross proceeds of about $413,366 (sales reported as 42,177 shares at a $9.75 weighted avg and 200 shares at $10.26).

Key Details

• Transaction date: 2026-02-24; Form 4 filed: 2026-02-26 (timely filing).
• Exercise: 42,377 shares acquired at $1.49 each (reported total ≈ $62,930).
• Sales: 42,177 shares @ weighted avg $9.75 (proceeds $411,314) and 200 shares @ $10.26 (proceeds $2,052). Total gross proceeds ≈ $413,366.
• Reported sale price range: $9.23 to $10.20 (weighted avg reported as $9.75). The filer can provide per-trade prices on request (footnote).
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted March 27, 2025 (footnote).
• Shares owned after these transactions are not specified in the supplied filing; these transactions alone resulted in no net change in shares from this exercise/sale pair (42,377 acquired and 42,377 sold).
• Not indicated as a 10% owner in the provided information.

Context

• This is a common “exercise then sell” (cashless-like) pattern: the insider exercised options to obtain shares and then sold those shares immediately (or the same day) under a pre-established 10b5-1 plan. Such transactions often reflect routine option exercises and planned sales rather than an unplanned market view; filings are factual records of transfer and proceeds, not explanations of motivation.